|
|
|
International Clinical Trials
|
Sarah Palit of Informa Life Sciences
talks to ICT about the upcoming Partnerships in Clinical Trials (PCT)
Europe event, held in Hamburg this November
ICT: PCT Europe is recognised as an international meeting place for decision
makers in the clinical outsourcing industry. But what makes the event
so special?
Sarah Palit: PCT is Europe’s leading industry update for all clinical development
outsourcing professionals, attracting more than 1,000 attendees. It
provides a practical and strategic look at how to improve the
relationship between clinical sponsors and their service providers, with
access to the largest expert speaker panel in Europe – over 150
presenters, including Vice Presidents, Directors and Heads of Clinical
Outsourcing. This year, we have more than 70 brand new case studies,
plus formal discussions and informal networking opportunities, which
will allow delegates to question the expert faculty and gain ideas that
can be implemented on returning to the office. Networking is a huge
benefit for PCT Europe’s attendees; we have Europe’s largest clinical
outsourcing exhibition ever with more than 130 service offering clinical
trial solutions.
What new session tracks will be featured at this year’s show?
PCT 2012 offers eight break-out streams and six break-out symposia. New
session tracks for 2012 include: strategically managing risk; tactics
for efficient operational delivery; critical examination of strategic
outsourcing models; planning and measuring project success; emerging
markets – gaining quality for value in emerging economies; strategic
relationship management and oversight; expert opinion track – update on
key industry challenges; and outsourcing strategies for small and
mid-size pharma and biotech. These exciting new streams include
presentations on real life examples and real data, plus panel sessions,
where the audience can join in with their viewpoints and questions.
PCT showcases an impressive range of speakers. Who should we look out for?
I would recommend looking out for Dave deBronkart ‘e-patient Dave’; who
will be explaining how, as an empowered patient, he beat Stage 4 cancer
by leading his own recovery, and the economic keynote talk from Joe
Nellis, Professor of International Management Economics, on the
competitive outlook for 2013 and beyond.
Emerging markets are playing an increasingly significant role in clinical outsourcing. Will PCT 2012 be covering this hot topic?
Yes, we’re delighted to announce our brand new stream: emerging markets –
gaining quality for value in emerging economies. Delegates attending
this stream will discover the real costs of running clinical trials in
other locations. We’re very excited about our speaker Wim Leereveld,
Founder and CEO of Access to Medicine Foundation. We’ll also have
presentations focusing on China, ensuring data quality and global
testing harmonisation in China, the MENA region and Asia-Pacific.
What makes Hamburg the ideal location to host PCT 2012?
We are very lucky that the PCT 2012 congress centre is located
conveniently in the middle of Hamburg, yet only five miles from Hamburg
International airport. Hamburg has a unique cultural life and the
Hamburg State Opera House is the oldest public opera house in Germany.
With more than 300 theatres, music venues, cabarets and a lively museum
and gallery scene, Hamburg boasts a cultural calendar of world-class
dimension. So if our delegates find the time around the busy PCT 2012
schedule to visit the city, we are sure they’ll have a fantastic time!
What plans are afoot for the 2013 meeting?
We are currently at the early stages of research, but we will use what
we learn at the 2012 event, especially from what’s talked about during
the discussion and debates. There’s currently a lot changing in the
outsourcing industry, including a lot of buzz around the effect of
private equity buying up CROs. How will this affect key stakeholders and
how will it change the clinical outsourcing landscape? We will address
what the key stakeholders really think about strategic partnerships. As
always, we will focus on cutting edge clinical outsourcing topics,
real-life case studies and practical experience from senior level
clinical outsourcing experts.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL
Detailed results from an updated analysis of the Phase III CASPIAN
trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a
choice of chemotherapies, etoposide plus either carboplatin or
cisplatin, demonstrated a sustained, clinically meaningful overall
survival (OS) benefit for adults with extensive-stage small cell lung
cancer (ES-SCLC) treated in the 1st-line setting.
More info >> |
|
 |
White Papers |
 |
|
Characterisation of Biopharmaceutical Proteins
Reading Scientific Services Ltd (RSSL)
Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Washington
27-29 September 2020, Walter E Washington Convention Center, Washington, US
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
